We found that CRB3 expression was negatively correlated with tamoxifen resistance in breast cancer patients and that tamoxifen‐resistant cells which overexpress CRB3 were more susceptible to tamoxifen treatment, reduced self‐renewal capability and suppressed the Wnt signalling pathway. This evidence concerns the gene CRB3 and breast carcinoma.